Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03902613 · ClinicalTrials.gov registry record · Phase 4
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03902613 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 1 participants.
The verdict
NCT03902613, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this project is to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, the project focuses on the importance of dopamine signaling in the process. Participants will have two different brain scans (MRI and PET scan). They will also have treatment for your depression with an FDA approved medication, lurasidone (Latuda). The study is funded by the Columbia University Irving Institute to improve the treatment of bipolar disorder.
Interventions
- DRUG Lurasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2019-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03902613
The ClinicalTrials.gov registry entry for NCT03902613 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurasidone is the first listed.
NCT03902613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03902613 about?
NCT03902613 is a clinical study titled "18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder". The goal of this project is to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, the project focuses on the importance of dopamine signaling in the process. Participants will have two different brain scans (MRI and PET scan). They will also have trea...
What is the current status of trial NCT03902613?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2019-02-07. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT03902613?
The interventions under investigation include: Lurasidone (DRUG).
Who is sponsoring clinical trial NCT03902613?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.